Mixed Serotonin 5-HT2A/2C Agonists with Reduced Hallucinogenic Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic-based drug therapies for psychological disorders are limited by their hallucinogenic effects, cardiotoxicity, and requirement for administration in a clinical setting under medical supervision.
Innovation Solution
Development of hallucinogenic and non-hallucinogenic serotonin receptor agonist compounds of Formula I, which can be administered privately without medical oversight, while maintaining the ability to modulate the 5-HT2A receptor without cardiotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin and LSD are used to treat depression and PTSD, then therapeutic effects are achieved through 5-HT2A receptor modulation, but hallucinogenic effects and cardiotoxicity occur due to strong agonistic effects at 5-HT2B receptor
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications at particular positions of the tryptamine core structure. By selectively modifying certain regions (positions 1-8 with specific substituents R1-R8), the compound achieves high affinity for 5-HT2A receptors while reducing activation of 5-HT2B receptors, thus providing therapeutic effects with minimized harmful effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and configurations on the tryptamine scaffold. By adjusting these molecular parameters, the compound's pharmacological profile is optimized to enhance 5-HT2A selectivity and reduce cardiotoxicity, transforming the drug's safety and efficacy characteristics.
2Reliability
If psychedelic drugs are administered to achieve therapeutic effects, then mood improvement occurs, but administration must be done in a clinical setting under medical supervision
Solution Approach 1:
The patent develops compounds with optimized pharmacokinetic properties including appropriate half-life and metabolic stability, allowing for controlled dosing regimens that can be administered outside clinical settings. The molecular structure is designed to provide sufficient duration of action for therapeutic effect while enabling safe home administration through predictable pharmacological profiles.
3Reliability
If tryptamine analogs are developed to maintain 5-HT2A receptor modulation, then therapeutic potential is preserved, but hallucinogenic and cardiotoxic effects persist
Solution Approach 1:
The patent applies segmentation by dividing the tryptamine molecule into functional segments: the core indole structure for receptor binding, the side chain at position 3 for modulating affinity and selectivity, and substitutable positions (R1-R8) for fine-tuning pharmacological properties. This segmented approach allows independent optimization of therapeutic effect versus harmful effects.
Solution Approach 2:
The patent creates composite molecular structures by combining the tryptamine core with various substituent groups at different positions. These composite structures integrate multiple functional elements that collectively achieve selective 5-HT2A agonism while minimizing 5-HT2B activation, thereby reducing cardiotoxicity and hallucinogenic effects.
Data Source
AI summary
Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.